Anika Therapeutics Financials
| ANIK Stock | USD 17.28 0.35 2.07% |
Anika |
Understanding current and past Anika Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Anika Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Anika Therapeutics' assets may result in an increase in income on the income statement.
Anika Therapeutics Stock Summary
Anika Therapeutics competes with Axogen, Orthofix Medical, SurModics, Paragon 28, and Artivion. Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 297 people.Specialization | Healthcare, Medical Devices |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0352551081 |
| CUSIP | 035255108 |
| Location | Massachusetts; U.S.A |
| Business Address | 32 Wiggins Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.anika.com |
| Phone | 781 457 9000 |
| Currency | USD - US Dollar |
Anika Therapeutics Key Financial Ratios
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0401 | ||||
| Target Price | 26.5 | ||||
| Number Of Employees | 357 | ||||
| Beta | 0.86 |
Anika Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anika Therapeutics's current stock value. Our valuation model uses many indicators to compare Anika Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anika Therapeutics competition to find correlations between indicators driving Anika Therapeutics's intrinsic value. More Info.Anika Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Anika Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Anika Therapeutics Systematic Risk
Anika Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Anika Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Anika Therapeutics correlated with the market. If Beta is less than 0 Anika Therapeutics generally moves in the opposite direction as compared to the market. If Anika Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Anika Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Anika Therapeutics is generally in the same direction as the market. If Beta > 1 Anika Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Anika Therapeutics January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Anika Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Anika Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Anika Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Anika Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anika Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.79 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 9.44 | |||
| Value At Risk | (2.64) | |||
| Potential Upside | 2.82 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.